February 13, 2018 / 3:18 PM / 2 months ago

BRIEF-Mologen Signs License Deal For China With Oncologie For Lead Compound Lefitolimod

Feb 13 (Reuters) - MOLOGEN AG:

* SIGNS LICENSE DEAL FOR CHINA AND GLOBAL CO-DEVELOPMENT AGREEMENT WITH ONCOLOGIE FOR LEAD COMPOUND LEFITOLIMOD

* SIGNED AGREEMENT IS CONDITIONAL UPON AN INITIAL PAYMENT OF EUR 3 MILLION RECEIVED BY MOLOGEN

* TOTAL PAYMENTS CAN AMOUNT TO ABOVE EUR 100 MILLION AND WILL BE PAID OVER SEVERAL YEARS

* ADDITIONALLY, MOLOGEN WILL RECEIVE LOW DOUBLE DIGIT ROYALTIES ON SALES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below